Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis

Arthritis and Rheumatism

Volumn 54, Issue 9, 2006, Pages 2997-3000

  Okuda, Yasuaki ^a,b   Takasugi, Kiyoshi ^a  

^a Dohgo Spa Hospital   (Japan)

^b Dohgo Spa Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; ANTIRHEUMATIC AGENT; ATLIZUMAB; AUROTHIOMALATE; BUCILLAMINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; RECEPTOR ANTIBODY; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG;

ADULT; AMYLOIDOSIS; ARTICLE; BLOOD LEVEL; CASE REPORT; DRUG DOSE REDUCTION; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL BIOPSY; GLAUCOMA; HUMAN; HUMAN TISSUE; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE OF ONSET; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE RHEUMATOID; BIOPSY; C-REACTIVE PROTEIN; FEMALE; GASTROINTESTINAL TRACT; HUMANS; RECEPTORS, INTERLEUKIN-6; SERUM AMYLOID A PROTEIN; TREATMENT OUTCOME;

EID: 33749331603     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22118     Document Type: Article

References (14)

1. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991;70:246-56.
2. Hazenberg BP, van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis [review]. Baillieres Clin Rheumatol 1994;8:661-90.
3. Gillmore JD, Lovat L, Persey MR, Pepys M, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid protein. Lancet 2001;358:24-9.
4. Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel allelic variant of serum amyloid A, SAA1 γ genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic amyloidosis. Hum Mol Genet 1995;4:1083-7.
5. Moriguchi M, Terai C, Kaneko H, Koseki Y, Kajiyama H, Uesato M, et al. A novel single-nucleotide polymorphism at the 5′-flanking region of SAA1 associated with risk of type AA amyloidosi secondary to rheumatoid arthritis. Arthritis Rheum 2001;44:1266-72.
6. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki Y. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004;314:363-9.
7. Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, et al. Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression. Genes Cells 2005;10:1051-63.
8. Mihara M, Shüna M, Nishimoto N, Yoshizaki K, Kishimoto T, Akamatsu K. Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis. J Rheumatol 2004;31:1132-8.
9. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis: phase I/II clinical study. J Rheumatol 2003;30:1426-35.
10. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9.
11. Elliott MJ, Woo P, Charles P, Long-Fox A, Woody JN, Maini RN. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-α (cA2). Br J Rheumatol 1997;36:589-93.
12. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
13. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571-3.
14. Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, et al. Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24.